Brief: Can Fite Announces First Patient Enrolled In Phase IIB Nash Clinical Trial With Namodenoson
31/01/2022 12:45
Jan 31 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB
NASH
CLINICAL TRIAL WITH NAMODENOSON
Source text for Eikon: ID:nBw5J1Csxa
Further company coverage: CANF.TA
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage